Treatment for Gonorrhea of the Glans Penis
Treat with ceftriaxone 500 mg intramuscularly as a single dose, and add doxycycline 100 mg orally twice daily for 7 days if chlamydial coinfection has not been excluded. This represents the most current CDC recommendation based on antimicrobial stewardship principles and evolving resistance patterns 1, 2.
Primary Treatment Regimen
The recommended first-line therapy for uncomplicated urogenital gonorrhea (including glans penis infection) is:
- Ceftriaxone 500 mg IM once 1, 2
- PLUS Doxycycline 100 mg orally twice daily for 7 days (if chlamydia not excluded) 1, 2
This represents an important update from older guidelines that recommended ceftriaxone 250 mg. The dose increase to 500 mg reflects antimicrobial stewardship priorities and provides higher tissue concentrations 1, 2.
Why This Regimen Changed
The 2020 CDC guidelines moved away from dual therapy with azithromycin due to:
- Rapid rise in azithromycin resistance (nearly 5% of isolates with elevated MICs by 2018) 1
- Antimicrobial stewardship concerns about unnecessary azithromycin exposure 1, 2
- Stable ceftriaxone MICs in the United States (< 0.1% with "alert value" MICs) 1
Azithromycin is preferred over doxycycline as the second agent when treating presumptively (before chlamydia results available), due to single-dose convenience 3.
Alternative Regimens
If Ceftriaxone Unavailable
- Cefixime 400 mg orally once
- PLUS Azithromycin 1 g orally once (preferred) OR Doxycycline 100 mg twice daily for 7 days
- PLUS Test-of-cure in 1 week 3
Important caveat: Cefixime provides lower and less sustained bactericidal levels than ceftriaxone and is no longer recommended as first-line due to rising MICs 3.
If Severe Cephalosporin Allergy
- Azithromycin 2 g orally once
- PLUS Test-of-cure in 1 week 3
Critical warning: This is a last-resort option only for true severe allergies. The high azithromycin dose causes significant gastrointestinal distress and resistance concerns 3.
Follow-Up Requirements
Routine test-of-cure is NOT required for uncomplicated urogenital gonorrhea treated with recommended ceftriaxone regimens 4, 5.
Test-of-cure IS required when:
- Alternative regimens used (cefixime or azithromycin monotherapy) 3
- Symptoms persist after treatment 4, 5
- Treatment failure suspected 3
Perform test-of-cure at 1 week after treatment completion, ideally with culture for antimicrobial susceptibility testing 3.
Critical Management Points
Treatment Failures
If symptoms persist after recommended treatment:
- Culture specimens and perform antimicrobial susceptibility testing 3
- Consult infectious disease specialist or CDC (404-639-8659) 3
- Report to local/state health department within 24 hours 3
- Consider pharyngeal coinfection (often asymptomatic) 6
Partner Management
- Treat all sexual partners from preceding 60 days before symptom onset or diagnosis 4, 5
- If last intercourse >60 days ago, treat most recent partner 4, 5
- Instruct patient to avoid sexual intercourse until treatment completed and both partners asymptomatic 4, 5
Concurrent Testing
Always test for:
- Chlamydia trachomatis (high coinfection rate) 4, 5
- HIV 7
- Consider syphilis screening based on local epidemiology 8
Common Pitfalls to Avoid
Do not use fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin) - widespread resistance makes these obsolete despite appearing in older guidelines 4
Do not use ceftriaxone 250 mg - the dose was increased to 500 mg in 2020 guidelines 1, 2
Do not routinely add azithromycin unless treating presumptively before chlamydia results or if chlamydia coinfection confirmed 1, 2
Do not skip partner treatment - reinfection is the most common cause of persistent symptoms, not treatment failure 4, 5
Do not assume urogenital treatment covers pharyngeal infection - pharyngeal gonorrhea is harder to eradicate and often asymptomatic 6